SCHEMBL2460739

SCHEMBL2460739

N[N+]12C=CN=CC1=C(C1=CC=C1)N=C2c1cccc(OCc2ccccc2F)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.38
F9 P00740 1/20 0.37
MAOB P27338 5/20 0.35
IGF1R P08069 1/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
KCNH2 Q12809 1/20 0.33
HPD P32754 1/20 0.32
PARP15 Q460N3 3/20 0.32
PARP10 Q53GL7 3/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PARP14 Q460N5 1/20 0.31
SCN3A Q9NY46 1/20 0.31
GSK3B P49841 1/20 0.30
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2462400 0.94 IGF1R (0.35) EGFRF9IGF1RMEN1KMT2A
SCHEMBL2461458 0.92 MEN1 (0.37) IGF1RHTTMEN1KMT2A
SCHEMBL2460564 0.91 IGF1R (0.36) EGFRIGF1R
SCHEMBL2461889 0.90 HPD (0.35) HPDMEN1KMT2A
SCHEMBL2460721 0.89 PTGER1 (0.35) EGFR
SCHEMBL2459926 0.89 NR1H2 (0.39) F9MAOBIGF1RLMNAMEN1
SCHEMBL2460704 0.89 PARP10 (0.31) PARP10
SCHEMBL2460315 0.89 NPC1 (0.38) LMNAPARP15PARP10MEN1KMT2A
SCHEMBL2458288 0.88 IDO1 (0.34) LMNA
SCHEMBL2463513 0.88 MEN1 (0.46) IGF1RLMNAKDM4EHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 EGFR 56/4885F9 4236/4885MAOB 1546/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 EGFR 56/4885F9 4236/4885MAOB 1546/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 EGFR 56/4885F9 4236/4885MAOB 1546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.